Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RODNEY S DANIEL

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1912094822
CMS profile
40909
Location
OLDSMAR, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$78,899.65

350 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 350 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RODNEY S DANIEL

NPI 1912094822 · CMS profile ID 40909

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

OLDSMAR, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 350 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912094822?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 350 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912094822?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 350 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912094822?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 350 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1912094822?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

350 matching records · $78,899.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 350 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 350.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $26.9207/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105420952 CMS
Amgen Inc. $23.4607/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550564 CMS
PFIZER INC. $6.6407/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131762270 CMS
Aurinia Pharma U.S., Inc. $26.8607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150678835 CMS
GENZYME CORPORATION $24.5607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139730204 CMS
Amgen Inc. $31.8407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550395 CMS
PFIZER INC. $22.0107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131611592 CMS
GENZYME CORPORATION $12.3507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139730228 CMS
GlaxoSmithKline, LLC. $25.1207/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115841918 CMS
Novartis Pharmaceuticals Corporation $25.1507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086889449 CMS
Amgen Inc. $17.2207/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550388 CMS
Alexion Pharmaceuticals, Inc. $25.3307/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093998057 CMS
Amgen Inc. $20.0007/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550554 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.0007/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118230946 CMS
GlaxoSmithKline, LLC. $32.9407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115829522 CMS
UCB, Inc. $1.4807/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143062155 CMS
UCB, Inc. $17.8707/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143062157 CMS
GlaxoSmithKline, LLC. $0.7407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116672890 CMS
Amgen Inc. $19.2107/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550444 CMS
ANI Pharmaceuticals, Inc. $32.3607/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091156958 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118230892 CMS
Novartis Pharmaceuticals Corporation $34.6806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086889447 CMS
UCB, Inc. $6.9606/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143062153 CMS
ANI Pharmaceuticals, Inc. $34.3406/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091170120 CMS
Amgen Inc. $15.3606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550650 CMS
Genentech USA, Inc. $13.5206/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133100604 CMS
Alexion Pharmaceuticals, Inc. $5,920.0006/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093970888 CMS
Alexion Pharmaceuticals, Inc. $65.7006/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093998324 CMS
Alexion Pharmaceuticals, Inc. $105.3506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094013582 CMS
Alexion Pharmaceuticals, Inc. $48.0006/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094021527 CMS
ABBVIE INC. $8.6006/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103598982 CMS
PFIZER INC. $8.8106/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131652809 CMS
Amgen Inc. $22.7706/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550536 CMS
Novartis Pharmaceuticals Corporation $34.6906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086889445 CMS
PFIZER INC. $21.6506/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131649474 CMS
Amgen Inc. $22.8006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115550435 CMS
GENZYME CORPORATION $20.1006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139730180 CMS
GlaxoSmithKline, LLC. $3.9206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115891853 CMS
UCB, Inc. $26.8006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143062151 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.4906/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118230908 CMS
Sandoz Inc. $19.9706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089372423 CMS
Alexion Pharmaceuticals, Inc. $12.8705/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093885586 CMS
Alexion Pharmaceuticals, Inc. $13.9405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093887977 CMS
Alexion Pharmaceuticals, Inc. $47.0805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093896320 CMS
Alexion Pharmaceuticals, Inc. $441.3505/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093916544 CMS
Alexion Pharmaceuticals, Inc. $30.3305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093936478 CMS
PFIZER INC. $17.2305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131493042 CMS
ABBVIE INC. $23.5305/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103598980 CMS
Alexion Pharmaceuticals, Inc. $124.2105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093892928 CMS
Alexion Pharmaceuticals, Inc. $316.3705/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093918827 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,884.13 344
PY2020 $28,991.20 290
PY2021 $24,014.60 308
PY2022 $70,718.82 328
PY2023 $101,428.20 375
PY2024 $78,899.65 350
PY2025 $144,949.74 377

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $584,620.11 33
PY2024 Recipient $114.46 1
PY2024 Principal investigator $159,238.66 12
PY2023 Principal investigator $51,533.02 2
PY2022 Principal investigator $463.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $13,460.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527756
Principal investigator 1 ABBVIE INC. $1,180.02 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522943
Principal investigator 1 ABBVIE INC. $4,252.50 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522945
Principal investigator 1 GlaxoSmithKline, LLC. $3,024.45 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146671
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,561.50 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190308240
Principal investigator 1 ABBVIE INC. $1,200.00 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202518443
Principal investigator 1 ABBVIE INC. $1,216.00 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202518445
Principal investigator 1 ABBVIE INC. $100.00 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202513769
Principal investigator 1 ABBVIE INC. $13,023.32 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202516349
Principal investigator 1 ABBVIE INC. $7,500.00 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202513139
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,104.90 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190308242
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146667
Principal investigator 1 ABBVIE INC. $3,676.66 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202508518
Principal investigator 1 GlaxoSmithKline, LLC. $3,087.81 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146675
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145544
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146679
Principal investigator 1 ABBVIE INC. $7,500.00 08/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202503837
Principal investigator 1 GlaxoSmithKline, LLC. $4,257.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145556
Principal investigator 1 ABBVIE INC. $2,280.00 07/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202498700
Principal investigator 1 GlaxoSmithKline, LLC. $3,158.10 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145539
Principal investigator 1 GlaxoSmithKline, LLC. $3,087.81 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145560
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202487869
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202487871
Principal investigator 1 GlaxoSmithKline, LLC. $3,131.37 05/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145564
Principal investigator 1 Eli Lilly and Company $4,148.83 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877551
Principal investigator 1 Eli Lilly and Company $49,426.00 04/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876791
Principal investigator 1 GlaxoSmithKline, LLC. $818.73 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145548
Principal investigator 1 GlaxoSmithKline, LLC. $11,307.78 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145535
Principal investigator 1 Eli Lilly and Company $5,385.29 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883098
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $200,475.00 01/16/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235998022
Principal investigator 1 GlaxoSmithKline, LLC. $6,219.18 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145552
Principal investigator 1 Eli Lilly and Company $171,228.00 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883096
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,309.86 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190309094